Tue, 02nd Feb 2021 17:05
LONDON, Feb 2 (Reuters) - The COVID-19 vaccine developed by
Oxford University and AstraZeneca has 76% efficacy against
symptomatic infection for three months after a single dose, with
efficacy improving when a second shot is given later, a preprint
study showed on Tuesday.
Oxford University said the findings supported a decision
made by Britain to extend the interval between initial doses and
booster doses of the shot to 12 weeks.
(Reporting by Alistair Smout
Editing by Gareth Jones)
(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in Lond...
Focus on Fed minutes, Nvidia earnings *
(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the B...
(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary ...
(Correcting London Stock Exchange index prices.)
Astrazeneca (AZN)